Skip to main content
PAHC logo

PAHC · Phibro Animal Health Corp

Track PAHC — free
$36.33 +1.15 (+3.27%)
Market Cap
$1.47B
Shares
40.56M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2022
Executive Total
Jack Bendheim $3,609,499
Jack C. Bendheim $3,609,499
Larry L. Miller $998,821
Rob Aukerman $807,440
Damian Finio $719,381
Daniel Bendheim $689,741
Fiscal 2021
Executive Total
Jack C. Bendheim $4,001,319
Jack Bendheim $4,001,319
Larry L. Miller $1,074,174
Daniel Bendheim $758,524
Thomas G. Dagger $746,880
Rob Aukerman $702,517
Damian Finio $681,912
Richard Johnson $511,830
Richard G. Johnson $511,830
Fiscal 2020
Executive Total
Richard Johnson $6,293,242
Richard G. Johnson $6,293,242
Jack C. Bendheim $3,023,918
Jack Bendheim $3,023,918
Larry L. Miller $819,305
Daniel Bendheim $644,331
Rob Aukerman $605,879
Thomas G. Dagger $596,253
Damian Finio
Fiscal 2019
Executive Total
Jack C. Bendheim $2,721,228
Jack Bendheim $2,721,228
Larry L. Miller $670,563
Richard Johnson $653,984
Richard G. Johnson $653,984
Thomas G. Dagger $564,065
Daniel Bendheim $452,782
Damian Finio
Fiscal 2018
Executive Total
Larry L. Miller $6,864,057
Jack C. Bendheim $3,410,331
Jack Bendheim $3,410,331

Executive changes

Person Change Filed
Daniel (Dani) Bendheim Appointed 2026-06-26
Joyce J. Lee Resigned 2026-04-14
Daniel (Dani) Bendheim Appointed 2025-12-18
Jack C. Bendheim Appointed 2025-12-18
Jack C. Bendheim Resigned 2025-12-18
Joyce J. Lee Appointed 2025-01-23
Todd Armstrong Appointed 2024-11-12
Rob Aukerman Retired 2024-11-12
Glenn C. David Appointed 2024-02-06
Richard G. Johnson Appointed 2023-09-05
Damian Finio Resigned 2023-09-05
Alejandro Bernal Appointed 2023-02-06
Damian Finio Appointed 2020-09-17
Richard G. Johnson Retired 2020-09-17
Key facts CIK 1069899 CUSIP 71742Q106 13F (30d) 189 filings 187 filers Visit website Investor relations